Skip to main content

Avasopasem + CDK4/6 Inhibitor and Hormonal Therapy

Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

  • RegistryNCT07137871
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMetastatic Hormone Receptor-Positive Breast Cancer
  • SponsorThe University of Texas Health Science Center at San Antonio
How Avasopasem worksNCT071378711 min

What the film says

Read the transcript

This trial is for adults with metastatic hormone receptor positive breast cancer that has progressed on a CDK4/6 inhibitor and hormonal therapy.

The idea: add avasopasem to the CDK4/6 inhibitor and hormonal therapy patients are already taking. The study looks at the safety of the combination and whether adding avasopasem improves how well the treatment works.

This phase 1 study plans 35 patients. At UT Health San Antonio, Kate Lathrop leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07137871

    Adults; metastatic HR+ breast cancer progressed on CDK4/6 inhibitor and hormonal therapy; Add avasopasem to ongoing CDK4/6 inhibitor and hormonal therapy; Safety and whether addition improves effectiveness; Phase 1; 35 patients (+1 more lines)

The drug

What is being tested.

Avasopasem has also been shown to exhibit both antitumor effects as well as minimal toxicity. Participants are currently taking a CDK 4/6 inhibitor and hormonal therapy

This is a phase 1 non-randomized clinical trial of Avasopasem in patients with metastatic hormone receptor positive breast cancer with progression on first line therapy consisting of a CDK 4/6 inhibitor and hormonal therapy to determine the efficacy and safety of the addition of Avasopasem in patients with metastatic HR+ breast cancer with progression after first line treatment with hormonal therapy (an AI or fulvestrant) and a CDK 4/6 inhibitor (ribociclib or abemaciclib).

Each treatment cycle will be 28 days and tumor assessment by imaging with CT scans of the chest, abdomen and pelvis will be performed every two cycles.

The study

How the trial runs.

This study aims to evaluate the safety of avasopasem in combination with CDK 4/6 inhibitor and hormonal therapy in women with metastatic hormone receptor positive breast cancer, and to see if the addition of avasopasem improves the effectiveness of a CDK 4/6 inhibitor and hormonal therapy.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed diagnosis of HR+, HER2 negative metastatic breast cancer.
  • Estrogen receptor (ER) and/or progesterone receptor (PR) expression positivity is defined as at least 10% of tumor cells nuclei positive by immunohistochemistry in the sample on testing.
  • HER2 negative: defined as IHC staining of 0 or 1+. If HER2 overexpression is equivocal by IHC, defined as 2+, the tumor must be non-gene amplified by FISH (ratio <2 and HER2 copy number <4).
  • Progression on treatment with a CDK 4/6 inhibitor and hormonal therapy in the metastatic setting
  • The CDK 4/6 inhibitor must be ribociclib or abemaciclib. Patients on palbociclib are not eligible.
  • Patient may have been on palbociclib previously but must have been stable on ribociclib or abemaciclib for at least three months prior to enrolling. In this case, the switch from palbociclib to either ribociclib or abemaciclib must have been of toxicity management and not progression of disease.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.